FR10C0016I1 - - Google Patents

Info

Publication number
FR10C0016I1
FR10C0016I1 FR10C0016C FR10C0016I1 FR 10C0016 I1 FR10C0016 I1 FR 10C0016I1 FR 10C0016 C FR10C0016 C FR 10C0016C FR 10C0016 I1 FR10C0016 I1 FR 10C0016I1
Authority
FR
France
Prior art keywords
antibodies
therapeutic uses
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22888581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0016(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR10C0016I1 publication Critical patent/FR10C0016I1/fr
Application granted granted Critical
Publication of FR10C0016I2 publication Critical patent/FR10C0016I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Lubricants (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR10C0016C 1994-05-02 2010-03-19 Procedes et compositions s'appliquant au traitement de la glomerulonephrite Active FR10C0016I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/236,208 US6074642A (en) 1994-05-02 1994-05-02 Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
PCT/US1995/005688 WO1995029697A1 (fr) 1994-05-02 1995-05-01 Procedes et compositions s'appliquant au traitement de la glomerulonephrite et d'autres maladies inflammatoires

Publications (2)

Publication Number Publication Date
FR10C0016I1 true FR10C0016I1 (fr) 2010-04-30
FR10C0016I2 FR10C0016I2 (fr) 2011-04-01

Family

ID=22888581

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0016C Active FR10C0016I2 (fr) 1994-05-02 2010-03-19 Procedes et compositions s'appliquant au traitement de la glomerulonephrite

Country Status (15)

Country Link
US (2) US6074642A (fr)
EP (5) EP2270047A3 (fr)
JP (5) JP3734266B2 (fr)
KR (2) KR100381128B1 (fr)
AT (1) ATE448791T1 (fr)
AU (1) AU2474795A (fr)
BR (1) BR9507594B8 (fr)
CA (2) CA2690298A1 (fr)
DE (2) DE122009000075I1 (fr)
DK (1) DK0758904T3 (fr)
ES (1) ES2336051T3 (fr)
FR (1) FR10C0016I2 (fr)
NL (1) NL300433I2 (fr)
PT (1) PT758904E (fr)
WO (1) WO1995029697A1 (fr)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
CA2198706C (fr) * 1994-09-23 2008-07-08 Yi Wang Procedes de traitement de l'arthrite
NZ506920A (en) 1998-02-20 2003-12-19 Tanox Inc Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
CA2377784A1 (fr) * 1999-06-29 2001-01-11 Gregory Collier Nouveaux genes et leur utilisation pour moduler l'obesite, le diabete et les desequilibres energetiques
DK2026073T3 (en) 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
ES2483991T3 (es) * 2000-10-10 2014-08-08 Genentech, Inc. Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
EP1998266A3 (fr) 2001-02-19 2009-02-11 Merck Patent GmbH Procédé d'identification d'épitopes de cellules t et utilisation pour préparer des molécules avec immunogénicité réduite
US20030109714A1 (en) * 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
CA2454562A1 (fr) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Procede d'amelioration de la fonction cognitive
EP1878441B1 (fr) 2001-08-17 2018-01-24 Genentech, Inc. Inhibiteurs de chemin d'accès complémentaires liant C5 et C5a sans empêcher la formation de C5b
DE60219801T3 (de) * 2001-08-17 2016-06-16 Genentech, Inc. KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
EP2298817A1 (fr) 2001-12-03 2011-03-23 Alexion Pharmaceuticals, Inc. Anticorps Hybrides
US20050221382A1 (en) * 2002-03-18 2005-10-06 Rother Russell P Stratification of patient populations having or suspected of having rheumatoid arthritis
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1545611B1 (fr) * 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Procede de traitement de l'asthme mettant en oeuvre des anticorps en complement du constituant c5
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2005072380A2 (fr) * 2004-01-28 2005-08-11 Chauhan Anil K Complexes d'attaque de membrane associees aux complexes immunitaires de circulation
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PL1755674T3 (pl) * 2004-05-14 2015-05-29 Alexion Pharma Inc Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
WO2007027906A2 (fr) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reactifs de detection de phosphorylation proteinique dans des voies de signalisation de leucemie
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
AU2006311803C1 (en) 2005-11-04 2015-05-14 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
PL1988882T3 (pl) * 2006-03-02 2015-04-30 Alexion Pharma Inc Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza
NZ571791A (en) * 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
EP3167888B1 (fr) * 2006-03-15 2024-05-01 Alexion Pharmaceuticals, Inc. Traitement de patients souffrant d'hémoglobinurie paroxystique nocturne par un inhibiteur de complément
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
EP2013235A1 (fr) * 2006-05-01 2009-01-14 Alexion Pharmaceuticals, Inc. Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
SI2061810T1 (sl) 2006-09-05 2015-04-30 Alexion Pharmaceuticals, Inc. Postopki in sestavki za zdravljenje s protitelesi povezanih nevropatij
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
WO2008048689A2 (fr) * 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Méthodes de traitement d'une dystrophie musculaire associée à une carence en dysferline
TWI391401B (zh) 2006-11-02 2013-04-01 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
EP1972639A3 (fr) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Réactifs pour la détection de la phosphorylation de protéines dans des voies signalant un carcinome
WO2008113834A2 (fr) * 2007-03-22 2008-09-25 Novartis Ag Antigènes c5 et leurs utilisations
EP1975184A3 (fr) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Sites de phosphorylation à sérine ou thréonine
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
EP1983003A3 (fr) 2007-04-19 2009-03-11 Peter Hornbeck Sites de phosphorylation à tyrosine et anticorps spécifiques
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983002A3 (fr) 2007-04-19 2009-03-11 Peter Hornbeck Sites de phosphorylation à tyrosine et anticorps spécifiques
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
CN102083861B (zh) * 2007-08-13 2016-04-13 瓦斯基因治疗公司 使用结合EphB4的人源化抗体的癌症治疗
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
JP5769968B2 (ja) 2007-10-18 2015-08-26 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ
EP2062920A3 (fr) 2007-11-21 2009-06-17 Peter Hornbeck Phosphorylation de protéines par des kinases de sérine/thréonine basophiles dans des voies de signalisation de l'insuline
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
NZ588507A (en) 2008-04-11 2012-11-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20090326070A1 (en) * 2008-05-01 2009-12-31 Complexa Inc. Vinyl substituted fatty acids
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
MY159396A (en) * 2008-08-05 2016-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
US20110165232A1 (en) * 2008-09-16 2011-07-07 Ak Kimya Ithalat-Ihracat Ve Sanayii Anonim Sirketi Use of Opioid Antagonists for the Preparation of a Medicament in the Treatment of Retinal Degenerative Diseases
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
NZ592786A (en) 2008-11-10 2013-02-22 Alexion Pharma Inc Methods and compositions for treating complement-associated disorders using eculizumab
DK2881402T3 (en) 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
US9028833B2 (en) 2012-12-13 2015-05-12 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
EP3903829B1 (fr) 2009-02-13 2023-05-03 Immunomedics, Inc. Immunoconjugués comportant une liaison intracellulaire clivable
SG173680A1 (en) 2009-02-24 2011-09-29 Alexion Pharma Inc Antibodies containing therapeutic tpo/epo mimetic peptides
US20100248265A1 (en) * 2009-02-27 2010-09-30 The Salk Institute For Biological Studies Compositions and methods for diagnosis and treatment of cancer
AU2010264520A1 (en) 2009-06-23 2012-01-19 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2011003098A1 (fr) 2009-07-02 2011-01-06 Musc Foundation For Research Development Procédés de stimulation de la régénération du foie
CA2774260C (fr) 2009-09-16 2018-10-09 Immunomedics, Inc. Anticorps anti-cea de classe i et leurs utilisations
TR201203732T1 (tr) * 2009-10-01 2012-09-21 Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
CA2782194C (fr) 2009-12-02 2018-01-16 Immunomedics, Inc. Combinaison d'anticorps radio-marquees et de conjugues anticorps-medicament pour le traitement du cancer pancreatique
CN102985106A (zh) * 2010-03-01 2013-03-20 阿雷克森制药公司 用于治疗德戈斯病的方法和组合物
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
CA2798120A1 (fr) * 2010-04-30 2011-11-03 Paul P. Tamburini Anticorps dont l'antigenicite pour l'humain est reduite
NZ629829A (en) 2010-04-30 2015-11-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
CA2803588A1 (fr) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Anticorps contre le fragment c3d du composant 3 du complement
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
WO2012019132A2 (fr) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Kinase des lymphomes anaplasiques dans le cancer du rein
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
EP2468295A1 (fr) 2010-12-21 2012-06-27 Affiris AG Vaccins à base de peptides de la proteine C5a du complement
WO2012115241A1 (fr) 2011-02-25 2012-08-30 中外製薬株式会社 Anticorps fc spécifique de fcγriib
EP2691101A2 (fr) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Administration et formulation d'acides nucléiques génétiquement modifiés
EP2700653B1 (fr) 2011-04-15 2019-07-24 SNU R&DB Foundation Complexe dans lequel un anticorps anti-cotinine est fixé à un matériau lieur de cotinine et une substance de liaison, et utilisation de celui-ci
CA2831572C (fr) 2011-05-02 2019-11-26 Immunomedics, Inc. Concentration d'ultrafiltration d'anticorps a allotype selectionne pour une administration de petit volume
EP2723361B1 (fr) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Méthodes de traitement de troubles chroniques au moyen d'inhibiteurs de complément
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP3492109B1 (fr) 2011-10-03 2020-03-04 ModernaTX, Inc. Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013090648A1 (fr) 2011-12-16 2013-06-20 modeRNA Therapeutics Nucléoside, nucléotide, et compositions d'acide nucléique modifiés
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
PT2817329T (pt) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polipeptioos que se ligam ao complemento humano c5
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
RU2655299C2 (ru) 2012-04-06 2018-05-24 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии
HUE037856T2 (hu) 2012-04-18 2018-09-28 Cell Signaling Technology Inc EGFR és ROS1 rákban
KR20200015952A (ko) 2012-06-18 2020-02-13 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
WO2014028560A2 (fr) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. Anticorps bispécifiques redirigés contre des cellules t pour le traitement de maladies
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
WO2017004144A1 (fr) 2015-07-01 2017-01-05 Immunomedics, Inc. Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
RU2663349C2 (ru) * 2013-01-31 2018-08-03 СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
SG11201507563SA (en) 2013-03-14 2015-10-29 Parkash Gill Cancer treatment using antibodies that bind cell surface grp78
SG11201507400SA (en) 2013-03-14 2015-10-29 Alnylam Pharmaceuticals Inc Complement component c5 irna compositions and methods of use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015023972A1 (fr) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Traitement du rejet de greffe consistant à administrer un inhibiteur du complément à un organe avant la transplantation
MX2016002397A (es) 2013-08-28 2016-09-08 Swedish Orphan Biovitrum Ab (Publ) Union de polipeptidos estables al componente 5(c5) de complemento humano.
AU2014314214C1 (en) 2013-08-28 2019-01-24 Affibody Ab Binding polypeptides having a mutated scaffold
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US20150104445A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
EP3080270B1 (fr) 2013-12-12 2021-10-27 Alnylam Pharmaceuticals, Inc. Composition d'arni d'élément de complément et procédés pour les utiliser
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US20170073754A1 (en) 2014-02-07 2017-03-16 Novartis Ag Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
CA2939626C (fr) * 2014-02-20 2023-01-17 Allergan, Inc. Anticorps anti-composant c5 de du systeme de complement
EP3107577B1 (fr) 2014-02-21 2024-03-20 IBC Pharmaceuticals, Inc. Traitement d'une maladie par induction d'une réponse immune à des cellules exprimant le trop-2
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
CA2940769A1 (fr) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Composes amines pour traiter les troubles a mediation par le complement
DK3107935T3 (da) * 2014-02-26 2020-09-21 Allergan Inc Komplementkomponent c5-antistoffer
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
PE20161440A1 (es) 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
EP4317445A3 (fr) 2014-05-05 2024-05-15 Regeneron Pharmaceuticals, Inc. Animaux c5 et c3 humanisés
NZ727420A (en) 2014-06-12 2018-06-29 Ra Pharmaceuticals Inc Modulation of complement activity
EP3160504B1 (fr) 2014-06-24 2020-09-16 Immunomedics, Inc. Thérapie par anti-histone pour nécrose vasculaire dans la glomérulonéphrite sévère
US10568568B2 (en) 2014-08-27 2020-02-25 Capnia, Inc. Methods for immune globulin administration
EP3191591A1 (fr) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant le composant du complément c5 et leurs méthodes d'utilisation
WO2016057398A1 (fr) 2014-10-07 2016-04-14 Immunomedics, Inc. Utilisation néoadjuvante de conjugués anticorps-médicaments
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
EP3207058A1 (fr) 2014-10-15 2017-08-23 Alexion Pharmaceuticals, Inc. Procédés de culture d'une cellule
WO2016061065A1 (fr) * 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Procédés pour modifier un profil isoélectrique d'un produit de protéine et leurs utilisations
WO2016094834A2 (fr) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Méthode de traitement d'une affection à médiation par le complément provoquée par un agent infectieux chez un patient
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
EP3988110A1 (fr) 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulateurs d'activité complémentaire
US20180087087A1 (en) 2015-03-25 2018-03-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
US20180074077A1 (en) 2015-03-25 2018-03-15 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
CA2981543A1 (fr) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolement, detection, diagnostic et/ou caracterisation de cellules cancereuses trop-2 positives
WO2016178980A1 (fr) 2015-05-01 2016-11-10 Alexion Pharmaceuticals, Inc. Efficacité d'un anticorps anti-c5 dans la prévention du rejet à médiation par les anticorps chez des receveurs sensibilisés d'une greffe de rein
EP3302529A4 (fr) 2015-06-03 2019-02-06 The Children's Hospital Medical Center Compositions et procédés pour le traitement de l'atrésie des voies biliaires néonatale
EP3307318A4 (fr) 2015-06-09 2019-01-16 Children's Hospital Medical Center Algorithme de dosage pour inhibiteur du complément
EP3307316A1 (fr) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation
EP3313443B9 (fr) 2015-06-25 2023-10-04 Immunomedics, Inc. Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoinositide 3-kinase améliorant considérablement un résultat thérapeutique de cancer
US20180142010A1 (en) * 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
WO2017035355A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés éther pour le traitement de troubles médicaux
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amide pour le traitement de troubles immunitaires et inflammatoires
WO2017035405A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles immunitaires et inflammatoires
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035361A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés disubstitués destinés au traitement de troubles médicaux
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035351A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles médicaux
EP3340983B1 (fr) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Composés aryle, hétéroaryle, et hétérocycliques pour le traitement de troubles immunitaires et inflammatoires
WO2017044811A1 (fr) 2015-09-11 2017-03-16 Bruce Andrien Variants d'éculizumab et d'éculizumab glycosylé de recombinaison
CA2997745A1 (fr) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methodes et compositions pour le traitement de la maladie de gaucher par l'intermediaire de la modulation du recepteur c5a
US11203634B2 (en) 2015-10-07 2021-12-21 Alexion Pharmaceuticals, Inc. Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
WO2017075252A1 (fr) 2015-10-30 2017-05-04 Genentech, Inc. Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
WO2017075325A1 (fr) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Procédé d'inhibition d'exacerbations de vasculopathies d'allogreffe médiées par les cellules t
WO2017075173A2 (fr) 2015-10-30 2017-05-04 Genentech, Inc. Anticorps et conjugués anti-facteur d
RS64067B1 (sr) 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
JP6088703B1 (ja) 2015-12-18 2017-03-01 中外製薬株式会社 抗ｃ５抗体および使用方法
RU2018141451A (ru) 2016-05-27 2020-06-29 Алексион Фармасьютикалс, Инк. Способы лечения рефрактерной генерализованной миастении
RU2018146778A (ru) 2016-06-07 2020-07-09 Новартис Аг Режим дозирования антитела к c5
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
EP4374922A3 (fr) 2016-06-14 2024-08-28 Regeneron Pharmaceuticals, Inc. Anticorps anti-c5 et leurs utilisations
PE20190394A1 (es) * 2016-06-17 2019-03-13 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso
JP7057290B2 (ja) 2016-06-27 2022-04-19 アキリオン ファーマシューティカルズ，インコーポレーテッド 医学的障害を治療するためのキナゾリン及びインドール化合物
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018071624A1 (fr) 2016-10-12 2018-04-19 Alexion Pharmaceuticals, Inc. Efficacité d'un anticorps anti-c5 dans la prévention du rejet médié par les anticorps chez des receveurs sensibilisés d'une greffe de rein
EP3526248A4 (fr) 2016-10-17 2020-07-08 Musc Foundation for Research Development Compositions et méthodes de traitement d'une lésion du système nerveux central
US11965884B2 (en) 2016-10-19 2024-04-23 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5 in a sample
WO2018075761A1 (fr) 2016-10-19 2018-04-26 Alexion Pharmaceuticals, Inc. Procédé de quantification de c5a non lié dans un échantillon
EP3532845A1 (fr) 2016-10-27 2019-09-04 Alexion Pharmaceuticals, Inc. Dosage de dépôt de c5b-9 dans des troubles associés au complément
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
CR20190403A (es) 2017-01-31 2019-10-10 Hoffmann La Roche Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
IL303696A (en) 2017-03-01 2023-08-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Composés pharmaceutiques destinés au traitement de troubles médicaux
WO2018160892A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Composés macrocycliques destinés au traitement de troubles médicaux
US11274146B2 (en) 2017-03-23 2022-03-15 The Trustees Of The University Of Pennsylvania Anti-C5a antibodies and uses thereof
EP3601336B1 (fr) 2017-03-31 2024-08-28 Alexion Pharmaceuticals, Inc. Procédé de quantification simultanée d'alxn1210 et d'éculizumab dans du sérum humain ou de l'urine
IL261809B2 (en) 2017-04-03 2024-04-01 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
JP2020517605A (ja) 2017-04-19 2020-06-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗ｃ５抗体の有効性
CA3059657A1 (fr) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversine pour le traitement de maladies bulleuses autoimmunes
EP3620531A4 (fr) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
WO2018217638A1 (fr) 2017-05-22 2018-11-29 Alexion Pharmaceuticals Inc. Dosage et administration d'anticorps anti-c5 pour le traitement d'une entéropathie à perte de protéine chez des patients
PT3658184T (pt) 2017-07-27 2023-11-29 Alexion Pharma Inc Formulações de anticorpo anti-c5 de elevada concentração
EP4424324A2 (fr) 2017-10-04 2024-09-04 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de patients présentant une glomérulonéphrite membranoproliférative
KR20200070355A (ko) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
WO2019089922A1 (fr) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c3 et leurs procédés d'utilisation
WO2019105916A1 (fr) 2017-11-29 2019-06-06 F. Hoffmann-La Roche Ag Dosage d'anticorps anti-médicament à interférence de cible supprimée
EP3717004A4 (fr) 2017-12-01 2021-12-01 Children's Hospital Medical Center Compositions pour le blocage des interérons et leurs méthodes d'utilisation
WO2019118556A1 (fr) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Associations d'anticorps anti-c5 et utilisations associées
BR112020026033A2 (pt) * 2018-06-19 2021-03-23 Atarga, Llc moléculas de anticorpo para complementar o componente 5 e usos das mesmas
AU2019315213B2 (en) 2018-08-01 2024-05-02 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
WO2020041301A1 (fr) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
JP2022500427A (ja) 2018-09-17 2022-01-04 国立大学法人京都大学 肝傷害又は肝不全の処置のための抗ｃ５剤の投与
US20200095307A1 (en) 2018-09-21 2020-03-26 Alexion Pharmaceuticals, Inc. Compositions and methods for the treatment of neuromyelitis optica
EP3856164B1 (fr) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Formes morphiques d'inhibiteurs du facteur d du complément
EA202191189A1 (ru) 2018-10-30 2021-08-06 Алексион Фармасьютикалс, Инк. Подкожное введение и дозировка антител к c5 для лечения пароксизмальной ночной гемоглобинурии (пнг)
US20210388070A1 (en) 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
US20220002393A1 (en) 2018-11-20 2022-01-06 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
CA3119234A1 (fr) 2018-11-23 2020-05-28 Silence Therapeutics Gmbh Acides nucleiques permettant d'inhiber l'expression de c3 dans une cellule
EP3730617A1 (fr) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Acides nucléiques pour inhiber l'expression de c3 dans une cellule
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
PT3914617T (pt) 2019-01-25 2024-05-31 Alexion Pharma Inc Dosagem e administração de anticorpos anti-c5 para tratamento da síndrome hemolítica urémica atípica (ahus)
WO2020242849A1 (fr) 2019-05-24 2020-12-03 Alexion Pharmaceuticals, Inc. Procédés de traitement du vitiligo à l'aide d'un anticorps anti-c5
CN114466660A (zh) 2019-07-31 2022-05-10 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
CN114929273A (zh) 2019-07-31 2022-08-19 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
WO2021026160A1 (fr) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la myasthénie grave généralisée réfractaire avec de l'eculizumab
CN114981430A (zh) 2019-08-27 2022-08-30 赛伦斯治疗有限责任公司 用于抑制细胞中的c3表达的核酸
TW202134435A (zh) 2019-10-22 2021-09-16 美商阿尼拉製藥公司 補體成分ｃ３ ｉｒｎａ組成物及其使用方法
JP2023507852A (ja) 2019-12-23 2023-02-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
WO2021154941A1 (fr) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Compositions d'arni du composant c5 du complément destinées à être utilisées dans le traitement de la sclérose latérale amyotrophique (sla)
WO2021178607A1 (fr) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant c3 du complément et leurs procédés d'utilisation pour le traitement ou la prévention de maladies associées au composant c3 du complément
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection
WO2021211940A1 (fr) 2020-04-16 2021-10-21 Assistance Publique, Hopitaux De Paris Méthodes de traitement d'un trouble médié par le complément provoqué par des virus
KR20230017789A (ko) 2020-04-30 2023-02-06 알닐람 파마슈티칼스 인코포레이티드 보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
CA3178589A1 (fr) 2020-05-12 2021-11-18 Mingjun Huang Utilisation d'inhibiteurs du facteur d du complement seuls ou en combinaison avec des anticorps anti-c5 pour le traitement de l'hemoglobinurie paroxystique nocturne
US20230235080A1 (en) 2020-06-03 2023-07-27 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
EP4165409A1 (fr) 2020-06-16 2023-04-19 F. Hoffmann-La Roche AG Procédé de détermination de l'antigène libre d'un anticorps dans un échantillon
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
EP4181958A4 (fr) * 2020-07-15 2024-03-06 Biosion, Inc. Anticorps se liant à la c5 et leurs utilisations
EP4274896A1 (fr) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Compositions d'arni du composant du complément 9 (c9) et leurs méthodes d'utilisation
US20240092881A1 (en) 2021-01-22 2024-03-21 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
CN116917326A (zh) 2021-01-22 2023-10-20 博泰康医药公司 抗her-2/trop-2构建体及其用途
JPWO2022239720A1 (fr) 2021-05-10 2022-11-17
EP4348263A1 (fr) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Procédés de détection de biomarqueurs cm-tma
WO2023023220A1 (fr) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la drépanocytose ou de la bêta-thalassémie à l'aide d'un inhibiteur de la voie alterne du complément
CA3230589A1 (fr) 2021-09-02 2023-03-09 Sibylle DAMES Acides nucleiques pour inhiber l'expression du facteur b du complement (cfb) dans une cellule
WO2023044048A1 (fr) 2021-09-17 2023-03-23 Novartis Ag Méthodes de prévention du rejet de greffe dans une xénogreffe
WO2023044370A2 (fr) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Compositions d'arni et procédés de silençage de composant du complément 3 (c3)
IL312399A (en) 2021-10-29 2024-06-01 Alnylam Pharmaceuticals Inc Complement factor B (CFB) iRNA compositions and methods of using them
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4845198A (en) 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4816565A (en) 1985-08-13 1989-03-28 Tasuku Honjo Interleukin 2 receptor and a method for production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5506247A (en) * 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2011450C (fr) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Chaine beta recombinante du recepteur d'il-2
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2671350A1 (fr) 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ATE220100T1 (de) 1991-12-20 2002-07-15 Yamanouchi Pharma Co Ltd Mit gp11b/iiia reaktive humane antikörper
JP3939747B2 (ja) * 1992-06-24 2007-07-04 アドプロテック・リミテッド 可溶性ｃｒ１誘導体

Also Published As

Publication number Publication date
BR9507594B8 (pt) 2015-06-02
KR100381128B1 (ko) 2003-09-29
DE69536017D1 (de) 2009-12-31
EP2270046A3 (fr) 2011-03-23
DE122009000075I1 (de) 2010-05-12
DK0758904T3 (da) 2010-01-18
JP4294596B2 (ja) 2009-07-15
EP0758904A1 (fr) 1997-02-26
JP5047996B2 (ja) 2012-10-10
BR9507594A (pt) 1997-09-16
EP0758904A4 (fr) 2005-04-20
JPH10500289A (ja) 1998-01-13
EP2270047A2 (fr) 2011-01-05
CA2690298A1 (fr) 1995-11-09
PT758904E (pt) 2010-02-10
ATE448791T1 (de) 2009-12-15
JP2012095650A (ja) 2012-05-24
US6355245B1 (en) 2002-03-12
ES2336051T3 (es) 2010-04-07
KR100442019B1 (ko) 2004-07-30
EP2298808A1 (fr) 2011-03-23
CA2189015A1 (fr) 1995-11-09
WO1995029697A1 (fr) 1995-11-09
NL300433I2 (en) 2010-04-01
US6074642A (en) 2000-06-13
EP0758904B1 (fr) 2009-11-18
EP2270047A3 (fr) 2011-03-23
JP2009165471A (ja) 2009-07-30
JP2005185286A (ja) 2005-07-14
EP2112165A3 (fr) 2011-03-23
KR20040000388A (ko) 2004-01-03
JP3734266B2 (ja) 2006-01-11
FR10C0016I2 (fr) 2011-04-01
JP2006020633A (ja) 2006-01-26
NL300433I1 (en) 2010-03-01
CA2189015C (fr) 2010-04-13
EP2270046A2 (fr) 2011-01-05
AU2474795A (en) 1995-11-29
EP2112165A2 (fr) 2009-10-28
BR9507594B1 (pt) 2010-08-10

Similar Documents

Publication Publication Date Title
FR10C0016I1 (fr)
DK0871631T3 (da) Antiparasitære marcfortiner og paraherquamider
EP0605442A4 (fr) Anticorps de recombinaison pour therapie humaine.
PL332541A1 (en) D-olanzapin dihydrate
EP0578819A4 (fr) Proteine apparentee a icam.
EP0805161A4 (fr) Proteine fixant le (1-3)-beta-d-glucane, anticorps reconnaissant la proteine et utilisation de la proteine et de l'anticorps
EP0650112A3 (fr) Source de courant constante.
GB9410512D0 (en) Novel treatment
EP0977590A4 (fr) Anticorps monoclonaux humains
PL313911A1 (en) Theraputic lamp
GB9411635D0 (en) Novel treatment
ZA941645B (en) Antibodies specifically reactive against human prostate specific antigen.
EP0667394A3 (fr) Anticorps recombiné produit par des bactéries Bacillus transformées.
IL116071A0 (en) Novel toxins
EP0617244A3 (fr) Réchauffeur d'air.
GB2305585B (en) Heat source
GB9423540D0 (en) Novel toxins
GB9501074D0 (en) Novel toxins
GB2300553B (en) Heat source
KR0112312Y1 (en) Pulleys
GB9314899D0 (en) Tumour-associated antigen
GB9401597D0 (en) Altered antibodies
HUP9903317A3 (en) Reconstituted human anti-hm 1.24 antibody
GB9504717D0 (en) Heat source
GB9504881D0 (en) Heat source